- Home
- AMSF vs ORKA Comparison
AMSF vs ORKA Comparison
Compare AMSF & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AMSF | ORKA |
|---|---|---|
| Founded | 1985 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Accident &Health Insurance | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 730.9M | 1.5B |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | AMSF | ORKA |
|---|---|---|
| Price | $38.49 | $31.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $58.33 | $48.20 |
| AVG Volume (30 Days) | 182.9K | ★ 643.8K |
| Earning Date | 10-29-2025 | 11-12-2025 |
| Dividend Yield | ★ 6.63% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.60 | N/A |
| Revenue | ★ $309,746,000.00 | N/A |
| Revenue This Year | $4.26 | N/A |
| Revenue Next Year | $4.48 | N/A |
| P/E Ratio | $14.85 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $36.34 | $5.49 |
| 52 Week High | $53.27 | $32.64 |
Technical Indicators
Market Signals| Indicator | AMSF | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 43.12 | 59.40 |
| Support Level | $37.85 | $27.84 |
| Resistance Level | $39.64 | $32.64 |
| Average True Range (ATR) | 0.81 | 1.93 |
| MACD | 0.03 | 0.08 |
| Stochastic Oscillator | 64.40 | 80.73 |
Price Performance
Historical ComparisonAbout AMSF AMERISAFE Inc.
AMERISAFE Inc is a specialty provider of workers' compensation insurance focused on small to mid-sized employers engaged in hazardous industries, principally construction, trucking, logging and lumber, agriculture, manufacturing, maritime, and telecommunications. The company generates a majority of its revenue in the form of premiums.
About ORKA Oruka Therapeutics Inc.
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.